H. Lundbeck A/S $HLUN-B.CO
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS9
PHASE 3 / 2-34
RECRUITING5
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO71%
Delay Index: of 7 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +21.1 months). See all sponsors →
Open H. Lundbeck A/S on the live radar map → 📅 $HLUN-B.CO readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| AMULET NCT05104476 |
P2 | Active, not recruiting | Multiple System Atrophy | 64 | 2023-11-16 (+6 mo) |
| Lu AG13909 NCT05669950 |
P1/2 | Recruiting | Congenital Adrenal Hyperplasia | 42 | 2026-09-30 (+21 mo) |
| PROSPECT-2 NCT04965675 |
P3 | Recruiting | Chronic Migraine in Children | 285 | 2027-03-26 (+30 mo) |
| PROSPECT-1 NCT05897320 |
P3 | Recruiting | Episodic Migraine | 315 | 2027-07-06 (+32 mo) |
| BalanCeD NCT06471829 |
P2 | Active, not recruiting | Cushing's Disease | 16 | 2027-08-10 (+18 mo) |
| MASCOT NCT06706622 |
P3 | Active, not recruiting | Multiple System Atrophy | 401 | 2028-02-17 |
| REJOIN NCT05164172 |
P3 | Recruiting | Migraine | 600 | 2028-04-30 (+32 mo) |
| DARE2 NCT07514858 |
P2 | Recruiting | Parkinson's Disease | 150 | 2028-10-03 |
| Asedebart NCT07859293 |
P2 | Not yet recruiting | Adrenal Hyperplasia, Congenital | 45 | 2031-07-31 |